Patents by Inventor Alain COUVINEAU

Alain COUVINEAU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYPEPTIDES FOR PREPARING DRUG CONJUGATES CAPABLE OF PROMOTING APOPTOSIS IN A CELL EXPRESSING AN OREXIN RECEPTOR
    Publication number: 20210188983
    Abstract: The present invention relates to polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor. In particular, the present invention relates to a polypeptide comprising the amino acid sequence of formula of X20-X21-X22-X23-G-X25-L-X27-X28 wherein: —X20 represents N, D, or K, —X21 represents H, A or Q, —X22 represents A, S, T or G, —X23 represents A, T or G, —X25 represents I or L, —X27 represents T or V and, —X28 represents M, L, V, Y or I.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 24, 2021
    Inventors: Bruno ROBERT, Pierre MARTINEAU, Alain COUVINEAU
  • Methods and pharmaceutical compositions for the treatment of cancer
    Patent number: 10894042
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: January 19, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Alain Couvineau, Valérie Gratio, Pascal Nicole, Thierry Voisin
  • Human monoclonal antibodies against orexin receptor type 1
    Patent number: 10758615
    Abstract: The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: September 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Alain Couvineau, Thierry Voisin, Pascal Nicole, Bruno Robert, Pierre Martineau, Myriam Chentouf
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY
    Publication number: 20190151304
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases. The inventors showed that orexin receptor antagonists have anti-inflammatory properties. Indeed, these compounds are antagonist for OX1R-mediated calcium mobilization but a full agonist for OX1R-mediated mitochondrial apoptosis, which is the mechanism involved in the improvement of resolution of inflammation observed in the models of colitis, multiple sclerosis and pancreatitis. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R antagonist.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 23, 2019
    Inventors: Yossan-Var TAN, Catalina ABAD RABAT, Thierry VOISIN, Alain COUVINEAU
  • USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
    Publication number: 20190083508
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases.
    Type: Application
    Filed: November 23, 2015
    Publication date: March 21, 2019
    Inventors: Alain COUVINEAU, Thierry VOISIN, Eric OGIER-DENIS, Nassima MESSAL, Valérie GRATIO, Pascal NICOLE
  • Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor
    Patent number: 10172921
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS
    Inventors: Alain Couvineau, Thierry Voisin, Nassima Messal, Eric Ogier-Denis, Xavier Treton
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS
    Publication number: 20180339022
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas. In particular, the present invention relates to an OX1R agonist for use in the treatment of hepatocellular carcinomain a subject in need thereof.
    Type: Application
    Filed: July 25, 2018
    Publication date: November 29, 2018
    Inventors: Alain COUVINEAU, Thierry VOISIN, Anne COUVELARD
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES
    Publication number: 20180305458
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory disease. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R agonist.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DIDEROT - PARIS 7, UNIVERSITÉ DE ROUEN NORMANDIE
    Inventors: Yossan-Var TAN, Catalina ABAD-RABAT, Alain COUVINEAU, Thierry VOISIN
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20180296549
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.
    Type: Application
    Filed: November 10, 2015
    Publication date: October 18, 2018
    Inventors: Alain COUVINEAU, Valérie GRATIO, Pascal NICOLE, Thierry VOISIN
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PANCREATIC CANCER
    Publication number: 20180064789
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of pancreatic cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of pancreatic cancer in a subject in need thereof.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 8, 2018
    Inventors: Thierry VOISIN, Anne COUVELARD, Alain COUVINEAU
  • OREXIN-B POLYPEPTIDES AND USES THEREOF
    Publication number: 20180044393
    Abstract: The present invention relates to Orexin-B polypeptides and uses thereof, in particular for the treatment of cancer. In particular, the polypeptide of the present invention comprises the amino acid sequence ranging from the amino acid residue at position 6 to the amino acid residue at position 28 in SEQ ID NO:2 wherein at least one amino acid residue position 6, 7, 8, 9, 10, 12, 13, 14, 19, 21 or 23 is substituted and the amino acid residues at position 11; 15; 16; 17; 18; 20; 22; 24; 25; 26; 27; and 28 are not deleted or substituted.
    Type: Application
    Filed: February 18, 2016
    Publication date: February 15, 2018
    Inventors: Alain COUVINEAU, Thierry VOISIN
  • HUMAN MONOCLONAL ANTIBODIES AGAINST OREXIN RECEPTOR TYPE 1
    Publication number: 20180030135
    Abstract: The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
    Type: Application
    Filed: January 14, 2016
    Publication date: February 1, 2018
    Inventors: Alain COUVINEAU, Thierry VOISIN, Bruno ROBERT, Pascal NICOLE, Myriam CHENTOUF, Pierre MARTINEAU
  • HUMAN MONOCLONAL ANTIBODIES AGAINST OREXIN RECEPTOR TYPE 1
    Publication number: 20180002421
    Abstract: The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
    Type: Application
    Filed: January 14, 2016
    Publication date: January 4, 2018
    Inventors: Alain COUVINEAU, Thierry VOISIN, Pascal NICOLE, Bruno ROBERT, Pierre MARTINEAU, Myriam CHENTOUF
  • Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
    Publication number: 20170319661
    Abstract: The present disclosure relates to methods and pharmaceutical compositions for the treatment of prostate cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of prostate cancer in a subject in need thereof.
    Type: Application
    Filed: December 3, 2014
    Publication date: November 9, 2017
    Inventors: Nicolas Chartrel, Youssef Anouar, Lydie Jeandel, David Alexandre, Jerome Leprince, Alain Couvineau, Thierry Voisin
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF OREXIN-1 RECEPTOR OX1R FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
    Publication number: 20170202925
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
    Type: Application
    Filed: June 23, 2015
    Publication date: July 20, 2017
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT - PARIS 7, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Alain COUVINEAU, Thierry VOISIN, Nassima MESSAL, Eric OGIER-DENIS, Xavier TRETON
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS
    Publication number: 20160339080
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas. In particular, the present invention relates to an OX1R agonist for use in the treatment of hepatocellular carcinomain a subject in need thereof.
    Type: Application
    Filed: January 22, 2015
    Publication date: November 24, 2016
    Inventors: Alain COUVINEAU, Thierry VOISIN, Anne COUVELARD